Advertisement

Breast Cancer Research and Treatment

, Volume 172, Issue 3, pp 597–601 | Cite as

Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure

  • Robert ThomasEmail author
  • Rachel Rowell
  • Siobhan Crichton
  • Henry Cain
Clinical trial
  • 112 Downloads

Abstract

Background

Primary endocrine therapy (PET) is a treatment option for elderly patients with ER-positive breast cancer enabling frail patients to avoid surgery. As a long-term treatment option, it has been shown to be inferior to surgery in controlling local disease. Decision-making in these patients is crucial in avoiding treatment failure. We examined the influence of decision-making on outcomes of PET failure as a secondary analysis as part of a large observational study.

Methods

Consecutive patients treated with PET between 2005 and 2015 for operable breast cancers were included in a retrospective observational study in 3 breast centres in the North-East. Treatment decision processes were examined by case note review and outcomes of treatment success or failure recorded.

Results

488 patients were included with mean follow-up of 31 months. Overall 63 (12%) experienced treatment failure. 227 (46.6%) were given a choice between surgery and PET at diagnosis. Logistic regression identified older age [OR 0.94 (0.91–0.96) p < 0.001] and reduced mobility [OR 0.6 (0.37–0.97) p 0.036] to be less likely offered surgery. Those offered surgery were more likely to experience treatment failure with PET [SHR 1.78 (1.05–3.02) p 0.033].

Conclusions

Despite a low failure rate in our series (literature failure rates vary between 12 and 85%), these results suggest that those actively offered a choice between surgery and PET are at greater risk of failure when choosing PET.

Keywords

Primary endocrine therapy Breast cancer Elderly 

Notes

Author contributions

RT and HC were responsible for the study concepts and design. Data acquisition was performed by RT and RR. Data and statistical analysis was performed by SC. Manuscript preparation, editing and review were performed by RT, RR, SC and HC.

Funding

No external funding or sponsorship was received by any author for the conduct of the study.

Compliance with ethical standards

Conflict of interest

HC receives honorariums and travel expenses from Roche Products Limited, Pfizer Inc. and Baxter Healthcare; no other relationships or activities exist for all other authors that could appear to have influenced the submitted work.

Ethical approval

No ethical approval was required for this retrospective study.

References

  1. 1.
    Preece PE, Wood RA, Mackie CR, Cuschieri A (1982) Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clinical research ed.). 284(6319):869CrossRefGoogle Scholar
  2. 2.
    Morgan JL, Reed MW, Wyld L (2014) Primary endocrine therapy as a treatment for older women with operable breast cancer: a comparison of randomised controlled trial and cohort study findings. Eur J Surg Oncol 30(6):676–684 40CrossRefGoogle Scholar
  3. 3.
    Hind D, Wyld L, Beverley CB, Reed MW (2006) Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) Cochrane Database Syst Rev 1: CD004272Google Scholar
  4. 4.
    Wylie S, Ravichandran D (2013) A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer. Ann R Coll Surg Engl 95(5):353–356CrossRefGoogle Scholar
  5. 5.
    Morgan JL, Richards P, Zaman O, Ward S, Collins K, Robinson T, Cheung KL, Audisio RA, Reed MW, Wyld L (2015) The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UK. Cancer Biol Med 12(4):308PubMedPubMedCentralGoogle Scholar
  6. 6.
    Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25(14):1824–1831CrossRefGoogle Scholar
  7. 7.
    Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I et al (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160CrossRefGoogle Scholar
  8. 8.
    National audit of breast cancer in older patients. Royal college of Surgeons. 2018 Annual report. Available from:https://www.nabcop.org.uk/reports/nabcop-2018-annual-report/
  9. 9.
    Thomas R, Rowell R, Crichton S, Cain H (2018 Jan) An observational study investigating failure of primary endocrine therapy for operable breast cancer in the elderly. Breast Cancer Res Treat 167(1):73–80CrossRefGoogle Scholar
  10. 10.
    Blair S, Robles J, Weiss A, Ward E, Unkart J (2016) Treatment of breast cancer in women aged 80 and older: a systematic review. Breast Can Curr Res 1:115Google Scholar
  11. 11.
    Bellavance EC, Kesmodel SB (2016) Decision-making in the surgical treatment of breast cancer: factors influencing women’s choices for mastectomy and breast conserving surgery. Front Oncol 6:74CrossRefGoogle Scholar
  12. 12.
    James R, McCulley SJ, Macmillan RD (2015) Oncoplastic and reconstructive breast surgery in the elderly. Br J Surg 102(5):480–488CrossRefGoogle Scholar
  13. 13.
    Mody L, Miller DK, McGloin JM et al (2008) Recruitment and retention of older adults in aging research. J Am Geriatr Soc 56(12):2340–2348CrossRefGoogle Scholar
  14. 14.
    Collins K, Reed M, Lifford K et al (2017) Bridging the age gap in breast cancer: evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial. BMJ Open 7:e015133CrossRefGoogle Scholar
  15. 15.
    Nicholson S, Halcrow P, Sainsbury JR, Angus B, Chambers P, Farndon JR, Harris AL (1988) Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58(6):810–814CrossRefGoogle Scholar
  16. 16.
    Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2013) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low income women. Am J Clin Oncol 36(2):181–187CrossRefGoogle Scholar
  17. 17.
    Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL (2011) A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer—final results at 20-year follow-up. Crit Rev Oncol 78(3):260–264CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Royal Victoria InfirmaryNewcastle Upon TyneUK
  2. 2.Newcastle Upon TyneUK
  3. 3.Medical Research Council Clinical Trials Unit at University College LondonLondonUK

Personalised recommendations